Amgen Inc. Q2 2026 Earnings Recap

Amgen’s shares rose 7.6% in response to better-than-expected growth across its key product portfolio, led by double-digit sales increases in six core growth drivers. The market rewarded the company’s clear acceleration in volume demand and margin performance despite ongoing biosimilar pressures.

Key Takeaways

• Total revenues surpassed $10 billion, up 10% year-over-year, powered by 22 products delivering double-digit growth.
• Six key growth drivers expanded 26% collectively, representing nearly 70% of total product sales, with standout performers including Repatha (+37%), EVENITY (+38%), TEZSPIRE (+42%), Rare Disease (+21%), Innovative Oncology (+18%), and Biosimilars (+29%).
• Repatha sales reached $953 million with new-to-brand prescriptions growing 50% year-over-year in the U.S., supported by broad access and strong clinical data.
• Margin performance remained solid despite increased investment in innovation and ongoing competition from biosimilars, particularly impacting Prolia and XGEVA, which declined 33%.
• Late-stage pipeline and technology investments continue advancing with a focus on expanding indications and geographic reach to sustain long-term durable growth.